Keywords: fda, panel, backs, approval, pfizer, sanofi-aventis, inhaled
FDA panel backs approval of Pfizer and Sanofi-Aventis' inhaled insulin Exubera
Article | 19 September 2005
US pharmaceutical giant Pfizer and France-based Sanofi-Aventis got a boost late-September 8, when a US Food and Drug Administration advisory committee ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- New study shows UCB's Neupro reduces NSBP in RLS patient
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
